Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Trial Profile

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evolocumab (Primary) ; HMG-CoA reductase inhibitors
  • Indications Atherosclerosis; Cardiovascular disorders; Hyperlipidaemia; Myocardial infarction; Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms FOURIER; PROFICIO
  • Sponsors Amgen
  • Most Recent Events

    • 13 Nov 2023 Results from FOURIER and FOURIER OLE assessing Long-Term Efficacy of Evolocumab in Patients With and Without Multivessel Coronary Artery Disease, presented at the American Heart Association Scientific Sessions 2023
    • 10 Nov 2023 Results presented in the Amgen Media Release
    • 10 Nov 2023 According to an Amgen media release, data from the study were presented at the American Heart Association (AHA) Scientific Sessions 2023 in Philadelphia.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top